Skip to content
My WebMD Sign In, Sign Up

Colorectal Cancer Health Center

Font Size

Drug Combo Stops Recurrent Colon Polyps

Researchers Say DFMO Plus Sulindac Less Toxic Than Chemotherapy
By
WebMD Health News
Reviewed by Louise Chang, MD

April 15, 2008 (San Diego) -- A combination of the targeted anticancer agent DFMO and the antiarthritis drug sulindac reduces the risk of recurrent colon polyps by up to 95%, researchers report.

Importantly, the combination was associated with less toxicity than chemotherapy, says study head Frank Meyskens, MD, director of the Cancer Center at the University of California at Irvine.

"This is the best thing that's come along for colon cancer prevention in 20 years," he tells WebMD.

The combination treatment worked so well that the study was halted early.

"We're all pretty excited," says Roy Herbst, MD. "The data is pretty extraordinary."

The study was presented here at the annual meeting of the American Association for Cancer Research. Herbst, a cancer specialist at the University of Texas M.D. Anderson Cancer in Houston, moderated the session.

Colorectal cancer will strike about 150,000 Americans in 2008. It will kill about 50,000 men and women, according to the American Cancer Society.

Reduction in Risk of Multiple Colon Growths

Meyskens and colleagues studied 375 people who had at least three colorectal polyps, also known as adenomas, removed.

They were randomly assigned to treatment with either a combination of DFMO and sulindac, or placebo.

After three years, colonoscopy exams showed that 12.3% of patients given the drug combination had developed a new polyp, compared with 41.1% of patients given a placebo. This translates to a 70% reduction in risk.

"Even more remarkable was that there was a 92% reduction in the risk of advanced adenomas that are more likely to go on to cancer," Meyskens says. A total of 0.7% of patients in the treatment group had advanced adenomas -- such as those that are 1 centimeter in size or larger or have signs of abnormal cell growth under the microscope (dysplasia) -- vs. 8.5% in the placebo group.

"The real home run: A 95% reduction in multiple adenomas," Meyskens says. A total of 0.7% of patients in the treatment group developed more than one adenoma, versus 13.2% in the placebo group.

There was no significant difference in the rate of serious side effects, including heart attacks and strokes, between the two groups.

Use Foreseen in People at High Risk of Colon Cancer

Meyskens says that DFMO, which is short for difluoromethylornithine, was developed as a cancer medication, but is now used to treat African sleeping sickness. It's also used to remove unwanted hair. Sulindac, a non-steroidal anti-inflammatory drug (NSAID), is also sold as Clinoril.

Meyskens says that further study is needed to confirm both the safety and effectiveness of the combo treatment. But he thinks it will eventually be used to help prevent colon cancer in "people at highest risk, such as people with advanced adenoma on colonoscopy."

It may also prove useful for "people with early colon cancer who have been cured. Without treatment, about one-third will go on to have another colon cancer," he says.

Today on WebMD

colorectal cancer slideshow
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
Colon Cancer Survival
VIDEO
Kemeny Chemo Side Effects
VIDEO
 

bread
ARTICLE
Colon vs Rectal Cancer
VIDEO
 
New Colorectal Treatments
VIDEO
can lack of sleep affect your immune system
FEATURE
 

Cancer Facts Quiz
QUIZ
Virtual Colonoscopy
VIDEO
 
Picture of the Colon
ANATOMY
Vitamin D
SLIDESHOW
 

WebMD Special Sections